CD274 and non-small cell lung carcinoma: In the first-line setting of NSCLC, the most effective treatments for patients with PD-L1 expressions of ≥50%, 1–49%, and <1% were atezolizumab, pembrolizumab/chemotherapy, and nivolumab/ipilimumab, respectively [42].